Latest

Changing Skies: Pharm Exec’s 2018 Industry Forecast

In our annual temperature check on the life sciences sector and its outlook for the months ahead, we explore eight trends that will shape the biopharma industry landscape in 2018.

Master Data Management 2.0

Using intelligent automation of content creation can turn master product data into business value, writes Siniša Belina.

Compliance Information at a Click

Tracy Rockney and Rob Merrill talk about their free regulatory compliance and information platform MyIndago, and why they think the industry needs it now.

Industry Trends 2018

12 Life Sciences Trends to Look Forward to in 2018

By Veeva Systems

Veeva Systems highlights its top 12 trends for the life sciences industry in 2018.

Syneos Health 2018 Trends Forecast

By Syneos Health

Syneos Health released its trends forecast, identifying 15 important trends that shape stakeholder perspectives, challenge conventional launch wisdom, and drive innovation affecting every aspect of the customer experience, starting with early clinical development and beyond.

"Value" Will Define the Next Year

By Cassandra Sinclair

Wunderman Health's Cassandra Sinclair discusses how value plays a role in the shifting landscape for 2018.

PharmExec Videos

New & Noteworthy

Q&A: From Gleevec to CAR-T

Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer and the related broader issues such as pricing and value and new innovations in cancer science.

mHealth: Changing the Dynamics of the Healthcare Ecosystem

mHealth devices and apps that continuously monitor patient symptoms and help with adherence also are likely to reshape medical practice – and with it the products pharma produce, writes Vicki Anastasi.

Prices and Competition to Shape the Year Ahead

States will continue to press for price controls, while FDA will tackle opioids and promote innovation.

New Year, Next Steps in Digital Transformation

Five predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.

Sales & Marketing

High Risk High Reward: Understanding, Embracing, and Aligning on Risks in Your Next Outcomes-Based Contract

Shared understanding of both risks and benefits to all parties in the healthcare continuum is essential in order to deliver more value, write Vickie Andros and Jake Caines.

The Reluctant Customer: Using Personas to Improve Compliance

Consumers of life sciences products are reluctant customers, and this reluctance can turn into non-compliance. Companies and providers need to understand patients at a human level, and what will motivate them to stay with a treatment plan.

New Targets for the Osteoporosis Market

Bagrat Lalayan presents an overview of osteoporosis treatment market and offers vision for future business strategies.

eBooks

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. 

View all eBooks

From the Editor

CAR-T Concerns for Continued Success

The advent of immunocellular therapies marks a major milestone in medical innovation, but the path for these treatments in transforming patient care is still forming as they face challenges in clinical trials, pricing, and market acceptance.

First Foray into Digital Adherence

FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.

PEspeaks

Trigger Emails for Healthcare Marketing

This post highlights the benefits of a new IT favorite for healthcare marketing, trigger emails.

High Risk High Reward: Understanding, Embracing, and Aligning on Risks in Your Next Outcomes-Based Contract

Shared understanding of both risks and benefits to all parties in the healthcare continuum is essential in order to deliver more value, write Vickie Andros and Jake Caines.

Drug Pricing Dominates Senate Hearing on HHS Nominee Azar

If confirmed as the next secretary of the Department of Health and Human Services (HHS), Alex Azar says that a top priority is to make drugs more affordable.

CAR-T Concerns for Continued Success

The advent of immunocellular therapies marks a major milestone in medical innovation, but the path for these treatments in transforming patient care is still forming as they face challenges in clinical trials, pricing, and market acceptance.

Compliance Top of Mind

There is never a lack of legal or regulatory issues to keep track of—and worry about—in the life sciences industry. The articles from Pharmaceutical Executive provide a look at the latest in compliance for marketing, labeling, and export control, as well as offer tips to stay compliant in the coming years.
 

Read More.

Interviews

Compliance Information at a Click

Tracy Rockney and Rob Merrill talk about their free regulatory compliance and information platform MyIndago, and why they think the industry needs it now.

Advancing the Safe Use of Healthcare Products

A quick-fire interview with J&J’s Joanne Waldstreicher about the company’s “Advancing the Safe Use of Healthcare Products QuickFire Challenge”.

EverlyWell CEO Draws on Outside Experience to Lead Health Company to Success

Julia Cheek recently landed in the television history books when she accepted a $1 million offer on the TV show “Shark Tank," the largest valuation for a solo female entrepreneur in the show’s history.

Regulatory

Drug Pricing Dominates Senate Hearing on HHS Nominee Azar

If confirmed as the next secretary of the Department of Health and Human Services (HHS), Alex Azar says that a top priority is to make drugs more affordable.

Tax Overhaul: A Plus for Pharma

Enacting landmark tax reform legislation that makes major changes in the corporate tax structure was Congress's Christmas present to President Trump — and to industry, writes Jill Wechsler.

New Report Stresses Importance of Affordable Drugs

Experts slam drug prices and endorse government price negotiations and curbs on drug advertising.

lorem ipsum